304 related articles for article (PubMed ID: 33021066)
1. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India.
Dravid A; Betha TP; Sharma AK; Gawali R; Mahajan U; Kulkarni M; Saraf C; Kore S; Dravid M; Rathod N
HIV Med; 2020 Oct; 21(9):578-587. PubMed ID: 33021066
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
5. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
TenoRes Study Group
Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472
[TBL] [Abstract][Full Text] [Related]
6. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
[TBL] [Abstract][Full Text] [Related]
8. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C; Molina JM; Cahn P; Lombaard J; Supparatpinyo K; Kumar S; Campbell H; Wan H; Teal V; Jin Xu Z; Asante-Appiah E; Sklar P; Teppler H; Lahoulou R;
Lancet HIV; 2024 Feb; 11(2):e75-e85. PubMed ID: 38141637
[TBL] [Abstract][Full Text] [Related]
10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of Tenofovir/Lamivudine/Dolutegravir among Antiretroviral Therapy Naive Human Immunodeficiency Virus Infected Patients of a Tertiary Care Center in Eastern India.
Sengupta D; Ghosh S; Pain S; Chatterjee N
J Assoc Physicians India; 2023 Sep; 71(9):72-74. PubMed ID: 38700305
[TBL] [Abstract][Full Text] [Related]
12. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
[TBL] [Abstract][Full Text] [Related]
13. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial.
Chen J; Chen R; Shen Y; Wei H; Wang X; Zhang R; Hu Z; Xie R; Huang Q; Wang J; Liu L; Qi T; Wang Z; Song W; Tang Y; Sun J; Lu H
Emerg Microbes Infect; 2020 Dec; 9(1):843-850. PubMed ID: 32267205
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
Villa G; Phillips RO; Smith C; Stockdale AJ; Ruggiero A; Beloukas A; Appiah LT; Chadwick D; Sarfo FS; Geretti AM
J Antimicrob Chemother; 2018 Nov; 73(11):3148-3157. PubMed ID: 30032305
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
Arrizabalaga J; Arazo P; Aguirrebengoa K; García-Palomo D; Chocarro A; Labarga P; Muñoz-Sánchez MJ; Echevarría S; Oteo JA; Uriz J; Letona S; Fariñas MC; Peralta G; Pinilla J; Ferrer P; Alvarez ML; Iribarren JA
HIV Clin Trials; 2007; 8(5):328-36. PubMed ID: 17956834
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
20. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
